[
  {
    "ts": "2026-02-02T12:00:00+00:00",
    "headline": "EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases",
    "summary": "New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated with monthly dosingTARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on Februar",
    "url": "https://finance.yahoo.com/news/eylea-hd-aflibercept-injection-8-120000940.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "30bc44f1-aa44-3871-8ba5-461646753372",
      "content": {
        "id": "30bc44f1-aa44-3871-8ba5-461646753372",
        "contentType": "STORY",
        "title": "EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases",
        "description": "",
        "summary": "New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated with monthly dosingTARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on Februar",
        "pubDate": "2026-02-02T12:00:00Z",
        "displayTime": "2026-02-02T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
          "originalWidth": 800,
          "originalHeight": 126,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ohIVokMiKClSVTQVwyB2lw--~B/aD0xMjY7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142.cf.webp",
              "width": 800,
              "height": 126,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YuYzNeQcIK6rRYN1HdT6UA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eylea-hd-aflibercept-injection-8-120000940.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eylea-hd-aflibercept-injection-8-120000940.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-02T17:51:10+00:00",
    "headline": "Regeneron 2026 Outlook Balanced With Dupixent Growth, Sanofi Collaboration, RBC Says",
    "summary": "Regeneron Pharmaceuticals' (REGN) 2026 is shaping up as a \"potentially balanced year,\" with Dupixent",
    "url": "https://finance.yahoo.com/news/regeneron-2026-outlook-balanced-dupixent-175110809.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "b230e931-6575-3b2f-9693-e69a4ade4fd9",
      "content": {
        "id": "b230e931-6575-3b2f-9693-e69a4ade4fd9",
        "contentType": "STORY",
        "title": "Regeneron 2026 Outlook Balanced With Dupixent Growth, Sanofi Collaboration, RBC Says",
        "description": "",
        "summary": "Regeneron Pharmaceuticals' (REGN) 2026 is shaping up as a \"potentially balanced year,\" with Dupixent",
        "pubDate": "2026-02-02T17:51:10Z",
        "displayTime": "2026-02-02T17:51:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-2026-outlook-balanced-dupixent-175110809.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-2026-outlook-balanced-dupixent-175110809.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            },
            {
              "symbol": "SNY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]